title: Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).
abstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine metabolism characterized by immunodeficiency, failure to thrive and metabolic abnormalities. A lack of the enzyme ADA allows accumulation of toxic metabolites causing defects of both cell mediated and humoral immunity leading to ADA severe combined immune deficiency (SCID), a condition that can be fatal in early infancy if left untreated. Hematopoietic stem cell transplant is curative but is dependent on a good donor match. Other therapeutic options include enzyme replacement therapy (ERT) with pegademase bovine (PEG-ADA) and more recently gene therapy. PEG-ADA has been used in over 150 patients worldwide and has allowed stabilization of patients awaiting more definitive treatment with hematopoietic stem cell transplant. It affords both metabolic detoxification and protective immune function with patients remaining clinically well, but immune reconstitution is often suboptimal and may not be long lived. We discuss the pharmacokinetics, immune reconstitution, effects on systemic disease and side effects of treatment with PEG-ADA. We also review the long-term outcome of patients receiving ERT and discuss the role of PEG-ADA in the management of infants and children with ADA-SCID, alongside other therapeutic options.
authors.affiliation: Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK.
authors.forename: Claire
authors.initials: C
authors.lastname: Booth
authors.forename: H Bobby
authors.initials: HB
authors.lastname: Gaspar
references.citation: J Exp Med. 2000 Jul 17;192(2):159-70
references.pmid: 10899903
references.citation: Pediatrics. 2005 Dec;116(6):e876-9
references.pmid: 16263974
references.citation: Lancet. 1975 Oct 18;2(7938):743-6
references.pmid: 52774
references.citation: Eur J Pediatr. 1992 Nov;151(11):811-4
references.pmid: 1468454
references.citation: Pediatr Res. 1993 Jan;33(1 Suppl):S42-7; discussion S47-8
references.pmid: 8433874
references.citation: Prenat Diagn. 1987 Oct;7(8):561-5
references.pmid: 3120171
references.citation: Br J Haematol. 1984 Jan;56(1):107-19
references.pmid: 6231047
references.citation: Clin Immunol. 2005 Nov;117(2):133-43
references.pmid: 16112907
references.citation: J Pediatr. 1988 Aug;113(2):312-7
references.pmid: 3260944
references.citation: Clin Exp Immunol. 1981 Dec;46(3):649-52
references.pmid: 7337981
references.citation: J Clin Invest. 1981 Aug;68(2):413-21
references.pmid: 7263861
references.citation: Pediatr Res. 1993 Jan;33(1 Suppl):S35-41
references.pmid: 8433873
references.citation: J Clin Invest. 2008 Sep;118(9):3132-42
references.pmid: 18688285
references.citation: N Engl J Med. 2009 Jan 29;360(5):447-58
references.pmid: 19179314
references.citation: Clin Diagn Lab Immunol. 2005 Jul;12(7):861-6
references.pmid: 16002636
references.citation: Nat Med. 2006 Apr;12(4):401-9
references.pmid: 16582916
references.citation: Clin Pediatr (Phila). 2000 Mar;39(3):183-6
references.pmid: 10752014
references.citation: J Biol Chem. 1977 Jun 10;252(11):3582-6
references.pmid: 16907
references.citation: Clin Immunol Immunopathol. 1995 Sep;76(3 Pt 2):S228-32
references.pmid: 7554473
references.citation: Clin Immunol Immunopathol. 1979 Nov;14(3):307-26
references.pmid: 498598
references.citation: J Pediatr. 2007 Jul;151(1):93-5
references.pmid: 17586199
references.citation: N Engl J Med. 1980 Aug 14;303(7):377-80
references.pmid: 6156414
references.citation: J Pediatr. 2001 Jul;139(1):44-50
references.pmid: 11445793
references.citation: J Clin Invest. 1999 Mar;103(6):833-41
references.pmid: 10079104
references.citation: Clin Immunol Immunopathol. 1978 Mar;9(3):287-92
references.pmid: 627115
references.citation: J Med Genet. 1987 Feb;24(2):93-6
references.pmid: 3560174
references.citation: Blood. 1992 Sep 1;80(5):1163-71
references.pmid: 1387561
references.citation: Best Pract Res Clin Haematol. 2004 Sep;17(3):505-16
references.pmid: 15498720
references.citation: J Clin Invest. 1992 May;89(5):1643-51
references.pmid: 1569204
references.citation: Eur J Haematol. 2007 Oct;79(4):338-48
references.pmid: 17680812
references.citation: N Engl J Med. 1996 May 23;334(21):1367-71
references.pmid: 8614422
references.citation: Eur J Immunol. 2005 Nov;35(11):3376-86
references.pmid: 16276484
references.citation: Mol Ther. 2006 Oct;14(4):505-13
references.pmid: 16905365
references.citation: Am J Pathol. 1985 Jul;120(1):157-69
references.pmid: 4014441
references.citation: Pediatr Res. 1990 Aug;28(2):127-30
references.pmid: 2395602
references.citation: J Clin Invest. 2000 Nov;106(9):1149-57
references.pmid: 11067867
references.citation: J Clin Invest. 1993 Aug;92(2):596-602
references.pmid: 8349799
references.citation: J Biol Chem. 2000 Oct 13;275(41):32114-21
references.pmid: 10908569
references.citation: Clin Immunol. 2007 May;123(2):139-47
references.pmid: 17300989
references.citation: Science. 1995 Oct 20;270(5235):475-80
references.pmid: 7570001
references.citation: Lancet. 1972 Nov 18;2(7786):1067-9
references.pmid: 4117384
references.citation: N Engl J Med. 1987 Mar 5;316(10):589-96
references.pmid: 3807953
references.citation: N Engl J Med. 1976 Dec 9;295(24):1337-43
references.pmid: 980079